New Hepatitis B Drug Shows Promise with 20% Cure Rate in Clinical Trials
New Hepatitis B Drug Trials Found A Functional Cure In 20% Patients: Liver Doc Explains
Image: News 18
A recent study has found that a six-month course of the experimental drug bepirovirsen, combined with standard antiviral therapy, can achieve a functional cure for hepatitis B in about 20% of patients. This significant finding was reported at a major liver health conference and published in The New England Journal of Medicine.
- 01The study involved two efficacy trials and showed that bepirovirsen could help 20% of participants achieve a functional cure.
- 02Hepatitis B is a leading cause of liver cancer, affecting over 240 million people globally, with India housing 10-15% of the world's carriers.
- 03Dr. Cyriac Abby Philips emphasized that while this is a milestone, it only benefits a small group of patients with specific conditions.
- 04The durability of the treatment's effects remains uncertain, as data is only available for six months post-treatment.
- 05Regular checkups and surveillance for liver cancer are essential even after achieving a functional cure.
Advertisement
In-Article Ad
India faces a significant burden of liver diseases, contributing to 18% of global liver-related deaths, primarily due to rising metabolic conditions. A recent study published in The New England Journal of Medicine revealed that a six-month treatment with the experimental drug bepirovirsen, alongside standard antiviral therapy, can achieve a functional cure in approximately 20% of hepatitis B patients. This finding was highlighted at Europe's largest liver health conference. Hepatitis B is a highly infectious disease that can lead to chronic liver issues and is a major cause of liver cancer. Dr. Cyriac Abby Philips, a senior consultant at The Liver Institute, noted that while this treatment marks a significant advancement, it is effective only for a limited group of patients. He stressed the importance of widespread testing for hepatitis B, as the virus can remain dormant and reactivate later. The study's findings indicate that while some patients may stop antiviral treatment after six months, ongoing monitoring is crucial due to the potential for the virus to return.
Advertisement
In-Article Ad
The findings from the study could significantly impact hepatitis B treatment protocols and patient outcomes in India, where the disease is prevalent.
Advertisement
In-Article Ad
Reader Poll
What do you think about the new hepatitis B treatment findings?
Connecting to poll...
Read the original article
Visit the source for the complete story.